Neuraxpharm Group’s leriglitazone bet advances as European regulators back a narrow pediatric label

Minoryx Therapeutics has moved closer to converting leriglitazone from a privately financed development program into a commercial rare-disease asset after European regulators recommended NEZGLYAL for a narrowly defined group of boys with cerebral adrenoleukodystrophy. The Committee for Medicinal Products for Human Use recommended marketing authorisation under exceptional circumstances for males aged two to 12 with non-gadolinium-enhancing brain lesions and minimal or no neurological impairment. A European Commission decision is expected by the end of September 2026. The regulatory advance strengthens the economic case for Minoryx Therapeutics’ European licensing agreement with Neuraxpharm Group, which includes milestone payments and development funding worth up to €258 million, alongside tiered double-digit royalties. The commercial opportunity remains constrained by a small initial patient population, annual regulatory obligations and the need to secure pricing, reimbursement and early diagnosis across multiple European healthcare systems.

Why the leriglitazone recommendation revives the economics of Minoryx Therapeutics’ Neuraxpharm partnership

Minoryx Therapeutics granted Neuraxpharm Group exclusive European commercial rights to leriglitazone in November 2022. The agreement included a significant double-digit upfront payment, milestone payments and development funding that could total as much as €258 million, together with material tiered double-digit royalties on future sales. Minoryx Therapeutics retained rights in the United States and most other global markets, while separate rights had already been licensed in China.

The agreement was attractive because it allowed Minoryx Therapeutics to retain substantial economic participation while placing European commercial execution with a specialist central nervous system company. Neuraxpharm Group has a direct presence in more than 20 European countries and is backed by funds advised by Permira, giving it the geographic infrastructure and private-equity support required to manage a rare-disease launch across fragmented national markets.

The positive CHMP opinion does not disclose which milestone payments have been earned or will become payable if the European Commission grants authorisation. It nevertheless moves the partnership closer to the regulatory and commercial events on which milestone economics are typically based. The decision also improves Minoryx Therapeutics’ negotiating position in markets outside Europe because leriglitazone would carry validation from a major regulator after years of clinical and financing uncertainty.

That validation is especially meaningful because the companies previously experienced a European refusal. In January 2024, the CHMP recommended rejecting an earlier NEZGLYAL application covering a broader population of male adults and children aged two years and older with cerebral adrenoleukodystrophy. The negative recommendation was maintained after re-examination in May 2024.

The new application was not simply a resubmission of the same commercial proposition. Minoryx Therapeutics returned with additional results from the pediatric NEXUS study and narrowed the requested label to boys aged two to 12 with non-enhancing brain lesions and Neurological Functional Scores of zero or one. The revised strategy concentrates on the patients for whom the evidence appears strongest and the disease may still be intercepted before extensive neurological damage develops.

From a business perspective, the smaller label reduces the immediate addressable population but increases the probability of reaching the market. A broad rejection generates no commercial revenue, while a narrow authorisation can establish prescribing experience, reimbursement precedents and a regulatory platform for later expansion. Minoryx Therapeutics can potentially use the European launch to support discussions about adult cerebral adrenoleukodystrophy, additional regions and other central nervous system indications, although each expansion will require its own evidence and regulatory review.

How exceptional-circumstances approval changes the commercial opportunity and evidence burden

The CHMP recommended NEZGLYAL under exceptional circumstances, a pathway used when comprehensive efficacy and safety data cannot reasonably be obtained because a disease is extremely rare, scientific knowledge is limited or conventional evidence generation is impractical. Any resulting authorisation would be subject to specific obligations reviewed annually by European regulators.

This pathway provides a route to commercialisation without demanding a traditional large randomized registration program in an exceptionally small pediatric population. It does not amount to a relaxed or permanent approval without oversight. Minoryx Therapeutics and Neuraxpharm Group will need to comply with post-authorisation evidence, pharmacovigilance and reporting requirements defined in the final European Commission decision.

The evidence supporting the recommendation came principally from the open-label NEXUS study. Of the 20 boys who could be evaluated, seven, or 35%, experienced clinically and radiologically arrested disease after receiving treatment for up to 96 weeks or until transplantation. Six of the nine patients who entered with gadolinium-negative lesions showed stabilisation, compared with one of 11 patients whose lesions were already gadolinium positive.

Those results help explain why the final proposed label excludes gadolinium-enhancing disease. The treatment effect appeared considerably stronger before the lesions showed evidence of active inflammatory progression and disruption of the blood-brain barrier. The commercial model will therefore depend heavily on identifying patients during a narrow early window rather than waiting until obvious neurological symptoms emerge.

That requirement makes diagnosis and surveillance part of the product strategy. Neuraxpharm Group previously said it planned to create a leriglitazone centre of excellence, work with patient organisations and improve screening and referral pathways. Those activities are not merely corporate outreach. They influence whether eligible boys are diagnosed while they still meet the imaging and neurological criteria in the anticipated label.

A rare-disease product can carry significant clinical and economic value even with a small population, but the narrow criteria create limits. The proposed indication does not cover adult men, boys with gadolinium-enhancing lesions, patients with more advanced neurological impairment or the wider population living with X-linked adrenoleukodystrophy. The initial revenue opportunity will therefore depend on the number of children identified through newborn screening, family testing and regular magnetic resonance imaging before the disease progresses.

Safety obligations could also influence adoption. The European Medicines Agency identified weight increase, eyelid oedema, leukopenia and neutropenia among the most common side effects observed in children. The agency also said treatment should be initiated and monitored by a physician experienced in neurodegenerative diseases, reinforcing that NEZGLYAL would be a specialist therapy rather than a broadly prescribed community medicine.

The exceptional-circumstances route creates a workable balance between access and uncertainty. Minoryx Therapeutics and Neuraxpharm Group gain the possibility of entering the market, while regulators preserve annual oversight and the ability to require continued evidence. Commercial success will depend on whether the companies can transform that evidence commitment into confidence among physicians, families, payers and national health authorities.

Why the positive opinion strengthens Minoryx Therapeutics’ private valuation without producing a public cashtag reaction

Minoryx Therapeutics and Neuraxpharm Group are privately held, so there is no public share-price reaction or cashtag through which investors can immediately express sentiment. The valuation impact will instead appear through private financing discussions, milestone receipts, partnership economics and the strategic value assigned to leriglitazone by existing or prospective investors.

Minoryx Therapeutics has raised more than €120 million since its formation and is supported by investors including Columbus Venture Partners, Criteria BioVentures, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures and Eurazeo-linked funds. The company also secured a €26.9 million non-dilutive grant in July 2025 through the European IPCEI Med4Cure initiative to support clinical validation of leriglitazone and research into additional rare central nervous system diseases.

The CHMP opinion improves the probability that those investments will produce a commercial return. It also reduces one of the largest binary risks facing a registration-stage biotechnology company by moving leriglitazone closer to its first approval. The improvement is not equivalent to eliminating regulatory risk because the European Commission decision remains pending and the final obligations could affect launch costs and product positioning.

The opinion also strengthens the strategic value of Minoryx Therapeutics’ retained rights. The company controls leriglitazone in the United States and most markets outside Europe and China, giving it the option to pursue additional partnerships, raise private capital or retain greater economics where it has sufficient resources. European authorisation could provide regulatory precedent and real-world evidence useful in those discussions, although other agencies will make independent decisions.

Neuraxpharm Group gains a potentially important orphan-disease product for its European central nervous system franchise. The company has historically commercialised psychiatric and neurological medicines, while the leriglitazone partnership represents a move deeper into rare diseases. A successful launch would give Neuraxpharm Group a proprietary growth platform with greater differentiation than a portfolio based predominantly on established products.

The private ownership structure limits financial transparency. Neither company has disclosed the expected price of NEZGLYAL, the forecast number of eligible European patients, the specific milestones connected to the CHMP or European Commission decisions, or the launch expenditure required across individual countries. The headline value of up to €258 million therefore represents contingent partnership economics rather than guaranteed near-term revenue for Minoryx Therapeutics.

How adult cALD and Rett syndrome studies could expand leriglitazone beyond the first European label

The initial pediatric indication would establish only the first layer of leriglitazone’s potential value. Minoryx Therapeutics is continuing the randomized Phase 3 CALYX study in adult men with progressive cerebral adrenoleukodystrophy. The company expects results by early 2028, and positive findings could support expansion into a population excluded from the proposed European pediatric label.

Adult expansion would materially alter the commercial opportunity because cerebral disease can emerge throughout the lives of males with X-linked adrenoleukodystrophy. The current recommendation is limited to boys, while Minoryx Therapeutics estimates that a substantial proportion of adult patients may eventually develop progressive cerebral disease. The adult program also offers the randomized, placebo-controlled evidence that was unavailable in the pediatric NEXUS study.

Minoryx Therapeutics is also evaluating leriglitazone in the Phase 2a TREE study for girls with Rett syndrome. The study is expected to provide a readout by the end of 2026. Success would broaden the platform beyond adrenoleukodystrophy and support the company’s argument that brain-penetrating PPAR gamma activation may address multiple disorders involving neuroinflammation, mitochondrial dysfunction and impaired neuronal function.

These programs create upside but also require continued capital. The €26.9 million grant reduces dilution and supports broader development, while the Neuraxpharm Group agreement provides development funding and potential milestones. Minoryx Therapeutics must still manage multiple trials, regulatory obligations and global partnership decisions before the full platform can be valued as more than a single-product rare-disease company.

The European Commission decision expected by the end of September 2026 is the immediate commercial catalyst. Approval would then shift attention toward the final label, post-authorisation obligations, launch preparation and country-level access. The transition from regulatory recommendation to patient use could be gradual because orphan medicines still require specialist centres, diagnostic pathways and reimbursement agreements.

The strategic importance of the CHMP opinion lies in changing leriglitazone from a repeatedly questioned asset into a potentially approvable product with defined European economics. Minoryx Therapeutics narrowed the population, generated additional pediatric evidence and returned after the 2024 refusal with a more defensible regulatory package. The narrower label limits the first commercial market, but it gives the company and Neuraxpharm Group a realistic foundation from which to pursue broader indications and territories.

Key takeaways from Minoryx Therapeutics’ leriglitazone recommendation and commercial outlook

• The positive CHMP opinion moves Minoryx Therapeutics closer to its first product approval and revives the value of a European licensing agreement with Neuraxpharm Group worth up to €258 million in upfront, milestone and development-related economics.
• Neuraxpharm Group holds exclusive European commercial rights and brings direct market infrastructure across more than 20 countries, while Minoryx Therapeutics retains rights in the United States and most other regions outside China.
• The proposed European label is limited to boys aged two to 12 with non-gadolinium-enhancing lesions and minimal neurological impairment, creating a small initial market but improving the probability of regulatory approval.
• Approval under exceptional circumstances would require specific continuing obligations reviewed annually, meaning commercialisation would begin alongside ongoing evidence and safety commitments.
• The NEXUS evidence showed disease stabilisation in six of nine evaluable boys with gadolinium-negative lesions, supporting intervention before inflammatory brain lesions become more advanced.
• Early diagnosis will be commercially essential because patients must be identified before they progress beyond the imaging and neurological criteria included in the proposed indication.
• Minoryx Therapeutics has raised more than €120 million and secured a separate €26.9 million non-dilutive European grant, providing financial support for leriglitazone and additional rare central nervous system programs.
• There is no public cashtag or daily stock reaction because Minoryx Therapeutics and Neuraxpharm Group are privately held, making milestone payments, private valuations and partnership activity the more relevant sentiment indicators.
• The CALYX Phase 3 study in adult men and the TREE Phase 2a study in Rett syndrome could materially expand leriglitazone’s addressable market if their results support further development.
• The European Commission decision expected by the end of September 2026 will determine whether the regulatory recommendation becomes a commercial launch opportunity.